The New York Times report highlights a single-infusion base-editing therapy that produced sustained LDL reductions in a small early trial, framing it as potentially curative. Yet the coverage underplays critical limitations: this remains an open-label, non-randomized phase-1 study with fewer than 20 participants, offering no control arm to distinguish treatment effects from regression to the mean or lifestyle changes. Peer-reviewed data from Verve Therapeutics' VERVE-101 program (NEJM 2024; small n=10, dose-escalation design) similarly showed PCSK9 editing and LDL drops of 40-55% at six months, but reported transient liver enzyme elevations and lacked long-term off-target sequencing beyond one year. A second observational cohort in Circulation (2023; n=1,200 PCSK9 loss-of-function carriers) links lifelong LDL lowering to 50% CVD risk reduction, yet these are genetic correlations, not interventional outcomes. The original piece misses equity implications: one-time therapies could widen disparities if priced like Zolgensma ($2M+), leaving population-level impact dependent on manufacturing scale-up and payer models that current cost-effectiveness models ignore. Broader patterns in durable genetic interventions (e.g., CAR-T durability data) suggest delivery bottlenecks and immunogenicity may constrain rollout far more than the NYT implies.